Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | MAOA | P21397 | 2/20 | 0.61 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MITF | O75030 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.56 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3842527 | 0.86 | MAPT (0.74) | MAPTALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL4455485 | 0.86 | ALDH1A1 (1.00) | MAPTALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL1331804 | 0.86 | ALDH1A1 (1.00) | MAPTALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL4446167 | 0.86 | ALDH1A1 (1.00) | MAPTALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL391385 | 0.86 | MAPT (0.74) | MAPTALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL2013073 | 0.86 | ALDH1A1 (1.00) | MAPTALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL65211 | 0.86 | ALDH1A1 (1.00) | MAPTALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL10576066 | 0.86 | ALDH1A1 (1.00) | MAPTALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL3843978 | 0.86 | MAPT (0.74) | MAPTALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL202864 | 0.86 | ALDH1A1 (1.00) | MAPTALDH1A1TDP1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051335-A1 | TAU-TUBULIN KINASE (TTBK) INHIBITOR COMPOUNDS | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2025-02-13 | — | — | US | disclosed |
| EP-4368182-A1 | TAU-TUBULIN KINASE (TTBK) INHIBITOR COMPOUNDS | Consejo Superior De Investigaciones Científicas - CSIC (ES) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023281149-A1 | TAU-TUBULIN KINASE (TTBK) INHIBITOR COMPOUNDS | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2023-01-12 | — | — | WO | disclosed |
| US-11289238-B2 | Compositions for the filling of high aspect ratio vertical interconnect access (VIA) holes | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210174983-A1 | COMPOSITIONS FOR THE FILLING OF HIGH ASPECT RATIO VERTICAL INTERCONNECT ACCESS (VIA) HOLES | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC | 2021-06-10 | — | — | US | disclosed |
| WO-2021112933-A1 | COMPOSITIONS FOR THE FILLING OF HIGH ASPECT RATIO VERTICAL INTERCONNECT ACCESS (VIA) HOLES | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) | 2021-06-10 | — | — | WO | disclosed |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN UNIVERSITY (US) | 2021-01-26 | — | — | US | disclosed |
| US-10696801-B2 | Hydrate inhibitor carrying hydrogel | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2020-06-30 | — | — | US | disclosed |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | CASE WESTERN UNIVERSITY (US) | 2019-10-01 | — | — | US | disclosed |
| EP-2346821-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | Exelixis, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2011071995-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010045580-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | EXELIXIS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2007079003-A2 | AMIDE INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | SCHERING AKTIENGESSELLSCHAFT (DE) | 2007-07-05 | — | — | US | disclosed |
| EP-0341295-B1 | PROCESS FOR PRODUCING 4,4'-DIBROMODIPHENYL ETHER | GREAT LAKES CHEMICAL CORP (US) | 1994-03-16 | — | — | EP | disclosed |
| EP-0341295-A1 | PROCESS FOR PRODUCING 4,4'-DIBROMODIPHENYL ETHER | GREAT LAKES CHEMICAL CORPORATION (US) | 1989-11-15 | — | — | EP | disclosed |
| US-4835322-A | Process for producing 4,4'-dibromodiphenyl ether | GREAT LAKES CHEMICAL CORPORATION (US) | 1989-05-30 | — | — | US | disclosed |
| US-4056553-A | INTERMEDIATES FOR MONOAZO DYES | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-11-01 | — | — | US | disclosed |
| US-4005069-A | DISPERSE DYES; POLYESTERS, POLYAMIDES, CELLULOSE ACETATE-TRIACETATE | SANDOZ LTD. (CH) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | GRK1, MTNR1A, MTNR1B | MAPT 2745/4885ALDH1A1 2397/4885TDP1 3290/4885 |
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | MAPT 4374/4885ALDH1A1 1337/4885TDP1 3351/4885 |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, TXNRD2, TXNRD1 | MAPT 689/4885ALDH1A1 607/4885TDP1 1935/4885 |
| US-20250051335-A1 | TAU-TUBULIN KINASE (TTBK) INHIBITOR COMPOUNDS | TTBK1, TTBK2, MAPT | MAPT 3/4885ALDH1A1 3733/4885TDP1 78/4885 |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | MAPT 2830/4885ALDH1A1 647/4885TDP1 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.